Advanced search
Publication Cover
Ocular Immunology and Inflammation Volume 32, 2024 - Issue 1
Submit an article Journal homepage
248
Views
2
CrossRef citations to date
0
Altmetric
Original Articles

Characteristics of Ocular Inflammatory Side Effects Associated with Immune Checkpoint Inhibitors in a Northern California Population

Ying Qiana Department of Ophthalmology, Kaiser Permanente Oakland Medical Center, Oakland, California, USACorrespondence[email protected]
View further author information
, MD,
Sarah Eppleyb Department of Ophthalmology, California Pacific Medical Center, San Francisco, California, USAView further author information
, MD MS,
David Baerc Department of Oncology, Kaiser Permanente Oakland Medical Center, Oakland, California, USAView further author information
, MD &
Ronald B. Mellesd Department of Ophthalmology, Kaiser Permanente Redwood City Medical Center, Redwood City, California, USAView further author information
, MD
Pages 98-104 | Received 07 Mar 2022, Accepted 12 Dec 2022, Published online: 13 Jan 2023

References

  • Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. Longo DL, ed. N Engl J Med. 2018;378(2):158–168. doi:10.1056/NEJMra1703481.
  • Fang T, Maberley DA, Etminan M. Ocular adverse events with immune checkpoint inhibitors. J Curr Ophthalmol. 2019;31(3):319–322. doi:10.1016/j.joco.2019.05.002.
  • Dalvin LA, Shields CL, Orloff M, Sato T, Shields JA. Review checkpoint inhibitor immune therapy systemic indications and ophthalmic side effects. Retina. 2018;38:1063–78. https://journals.lww.com/retinajournal
  • Sun MM, Kelly SP, Mylavarapu BS, et al. Ophthalmic immune-related adverse events after anti-CTLA-4 or PD-1 therapy recorded in the american academy of ophthalmology intelligent research in sight registry. Ophthalmology. 2021;128(6):910–919. Elsevier Inc.; 2020. doi:10.1016/j.ophtha.2020.11.001.
  • Braun D, Getahun D, Chiu VY, et al. Population-based frequency of ophthalmic adverse events in melanoma, other cancers, and after immune checkpoint inhibitor treatment. Am J Ophthalmol. 2021;224:282–291. doi:10.1016/j.ajo.2020.12.013.
  • Dimitriou F, Urner-Bloch U, Eggenschwiler C, et al. The association between immune checkpoint or BRAF/MEK inhibitor therapy and uveitis in patients with advanced cutaneous melanoma. Eur J Cancer. 2021;144:215–223. doi:10.1016/j.ejca.2020.11.027.
  • Vanderbeek BL, Xia T, Brucker AJ, Mcgeehan B. Risk of non-infectious uveitis or myasthenia gravis in patients on checkpoint inhibitors in a large healthcare claims database. British J Ophthalmol. 2020;1–4. [ Published online]. doi:10.1136/bjophthalmol-2020.
  • Fortes BH, Liou H, Dalvin LA. Ophthalmic adverse effects of immune checkpoint inhibitors: the mayo clinic experience. Br J Ophthalmol. 2021;105(9):1263–1271. doi:10.1136/bjophthalmol. Published online 2010.
  • Bitton K, Michot JM, Barreau E, et al. Prevalence and clinical patterns of ocular complications associated with anti-PD-1/PD-L1 anticancer immunotherapy. Am J Ophthalmol. 2019;202:109–117. doi:10.1016/j.ajo.2019.02.012.
  • Conrady CD, Larochelle M, Pecen P, Palestine A, Shakoor A, Singh A. Checkpoint inhibitor-induced uveitis: a case series. Graefes Arch Clin Exp Ophthalmol. 2018;256(1):187–191. doi:10.1007/s00417-017-3835-2.
  • Kim JM, Materin MA, Sznol M, et al. Ophthalmic immune-related adverse events of immunotherapy: a single-site case series. Ophthalmology. 2019;126(7):1058–1062. doi:10.1016/j.ophtha.2019.01.031.
  • Noble CW, Gangaputra SS, Thompson IA, et al. Ocular adverse events following use of immune checkpoint inhibitors for metastatic malignancies. Ocul Immunol Inflamm. 2020;28(6):854–859.doi:10.1080/09273948.2019.1583347.
  • Papavasileiou E, Prasad S, Freitag SK, Sobrin L, Lobo AM. Ipilimumab-induced ocular and orbital inflammation - A case series and review of the literature. Ocul Immunol Inflamm. 2016;24(2):140–146. doi:10.3109/09273948.2014.1001858.
  • Gordon N. Similarity of the adult kaiser permanente membership in Northern California to the insured and general population in Northern California. Statistics from the 2011 California Health Interview Survey. 2015.
  • Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373(1):23–34. doi:10.1056/nejmoa1504030.
  • Antoun J, Titah C, Cochereau I. Ocular and orbital side-effects of checkpoint inhibitors: a review article. Curr Opin Oncol. 2016;28(4):288–294. doi:10.1097/CCO.0000000000000296.
  • Mantopoulos D, Kendra KL, Letson AD, Cebulla CM. Bilateral choroidopathy and serous retinal detachments during ipilimumab treatment for cutaneous melanoma. JAMA Ophthalmol. 2015;133(8):965–966. doi:10.1001/jamaophthalmol.2015.1114.
  • Wong RK, Lee JK, Huang JJ. Bilateral drug (Ipilimumab)-Induced vitritis, choroiditis, and serous retinal detachments suggestive of Vogt-Koyanagi-Harada syndrome. Retin cases Br Rep. 2012;6(4):423–426. doi:10.1097/ICB.0b013e31824f7130.
  • Ng CC, Alsberge JB, Qian Y, Freund B, Cunningham ET. Vogt-Koyanagi-Harada-like uveitis followed by melanoma-associated retinopathy with focal chorioretinal atrophy and choroidal neovascularization in a patient with Metastatic Cutaneous Melanoma O F. doi:10.1097/ICB.0000000000001113.
  • Kim YJ, Lee JS, Lee J, et al. Factors associated with ocular adverse event after immune checkpoint inhibitor treatment. Cancer Immunology, Immunotherapy. 2020;69(12):2441–2452. doi:10.1007/s00262-020-02635-3.
  • Strandberg-Larsen M, Schiøtz ML, Silver JD, et al. Is the Kaiser permanente model superior in terms of clinical integration?: a comparative study of Kaiser permanente, Northern California and the Danish healthcare system. BMC Health Services Research. 2010;10. https://www.biomedcentral.com/1472-6963/10/91

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.